Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michele Lambert

Pediatric Hematology-Oncology Philadelphia, PA Medical Doctor

NPI 1407886807 CMS profile 336454

3401 Civic Center Blvd, Children's Hospital Of Philadelphia - Hem/Onc, Philadelphia, PA 19104

Open in the dashboard

General payments

$62,073

46 records reported · program years 2019–2025

Research payments

$2,694

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$338,117 paid to institutions, not to them · program years 2020–2025

Through program year 2025, Michele Lambert of Philadelphia, PA is reported in the CMS Open Payments database as having received $62,073 across 46 general payments and $2,694 in research payments paid to them. Separately, studies naming them as principal investigator received $338,117 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 92nd percentile of Pediatric Hematology-Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $17,024 10
2025 Research $500 1
2023 General $2,988 4
2022 General $9,082 13
2021 General $13,304 7
2020 General $11,020 4
2019 General $8,655 8
2019 Research $2,194 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michele Lambert
  • Pediatric Hematology-Oncology median
  • Middle half of Pediatric Hematology-Oncology
  • National median

In program year 2025, general payments to Michele Lambert were reported at $17,024. Among 1,352 Pediatric Hematology-Oncology profiles paid that year, the median was $204 and the middle half received between $80 and $2,819.

Show as a table
Year Michele Lambert Pediatric Hematology-Oncology median Middle half National median
2019 $8,655 $184 $69–$2,094 $163
2020 $11,020 $220 $37–$3,941 $114
2021 $13,304 $366 $63–$4,909 $132
2022 $9,082 $181 $66–$2,775 $149
2023 $2,988 $175 $62–$2,600 $160
2024 $0 $227 $66–$2,992 $164
2025 $17,024 $204 $80–$2,819 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Dova Pharmaceuticals $14,873 7 payments
  2. Novartis Pharmaceuticals Corporation $11,581 4 payments
  3. Sobi, Inc $7,917 6 payments
  4. Janssen Research & Development, LLC $7,020 12 payments
  5. Novo Nordisk Inc $6,205 4 payments
  6. Argenx US, Inc. $5,625 2 payments
  7. Genzyme Corporation $4,298 3 payments
  8. Rigel Pharmaceuticals, Inc. $4,093 4 payments
  9. Alexion Pharmaceuticals, Inc. $150 1 payment
  10. Galderma Laboratories, L.P. $147 1 payment
  11. Other $164 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $48,319 15 payments
  2. Grant $6,205 4 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,750 2 payments
  4. Travel and Lodging $2,654 9 payments
  5. Food and Beverage $995 15 payments
  6. Honoraria $150 1 payment
Products named General payments · program years 2019–2025
  1. Doptelet Hematology/Oncology $17,597 9 payments
  2. PROMACTA $11,540 3 payments
  3. Doptelet Hepatology $5,193 4 payments
  4. VYVGART $5,000 1 payment
  5. Tavalisse $4,093 4 payments
  6. Soliris $150 1 payment
  7. ORACEA $147 1 payment
  8. AKLIEF $147 1 payment
  9. EPIDUO FORTE $147 1 payment
  10. Nplate $119 1 payment
  11. Other $86 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Octapharma USA, Inc. $2,194 1 payment
  2. Genzyme Corporation $500 1 payment

Records

48 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Hematology-Oncology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record